Disclaimer

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes.

No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease.
Drug Delivery Platform Innovator

DehydraTECH™ - Patented technology, Changing the way Active Pharmaceutical Ingredients ("APIs") enter the body orally

- Masks unwanted taste
- Improves speed of onset
- Increases bioavailability
- Simple and cost effective

Eliminates the need for sugar-filled edibles.
Effects are felt within 10-20 min (vs. 60-120 min).
Equates that of less healthy administration methods like inhalation
Easy to implement
DehydraTECH™ Patent Portfolio

- **Method of use & Composition of matter claims**
  - Cannabinoids (CBD, THC)
  - Nicotine (and its analogs)
  - NSAIDs
  - Fat soluble vitamins

- **Multiple dosage forms** - foods, liquid emulsions, tablets, capsules

- **50+ Patent Applications**
- **10 Patents Granted**
  - 6 USA
  - 4 Australia
- **10 Patent Families**

Investor Presentation
Commercial Applications

- **Cannabis**
  - Ingestible product formats of all types,
  - Enhanced palatability, speed of effectiveness and potency,
  - Viable and healthier alternative to smoking/vaping.

- **Vitamins**
  - Existing and new ingestible product formats,
  - Enhanced absorption performance for synthetics as well as natural fat soluble vitamins (A, D, K & E).

- **NSAIDs**
  - Alternate means to formulate NSAIDs,
  - Higher bioavailability,
  - Lower input requirements,
  - Less burden on liver and kidneys (lower toxicity).

- **Nicotine**
  - World’s first ingestible nicotine products,
  - Alternative to smoking/vaping, gums and patches,
  - High bioavailability without first pass liver metabolism.

**Estimated Global Market Sizes**

- Cannabis: $13B
- Vitamins: $31B
- NSAIDs: $60B
- Nicotine: $990B

Sources: ArcView Research & EuroMonitor
Cannabinoids: Entering the Blood Stream

3 prominent ways cannabinoids enter the blood stream:

- **Inhalation**
  - High bioavailability (est. 30%)
  - Harmful to Lungs

- **Sub-lingual (under tongue)**
  - Medium bioavailability (est. 16%)
  - Foul taste

- **Oral – Gastrointestinal Tract**
  - Low bioavailability (est. 3-5%)
  - Sugar filled, to mask taste

---

**DehydraTECH™**
transforms the way cannabinoids enter the bloodstream through the Gastrointestinal Tract

- Fast Acting
- Improved Taste
- Increased Bioavailability
Cannabinoid Absorption - Clinically Proven

European human clinical study

Double-blind
90 mg dose

317% more CBD delivered ≤ 30 min.

Higher CBD delivery throughout entire study

Plasma Concentration Comparison

TurboCBD™
DehydraTECH™
Control

Plasma concentration (ng/mL)

Time (min)
Cannabis Consumption Trends

DehydraTECH™
Improves alternate delivery methods

Trend away from smoking

DehydraTECH™
Improves cannabinoid absorption

Trend to limit dosage in edibles

Trend toward beverages & edibles

DehydraTECH™
spans foods, beverages, nutritional supplements and more
**Business Model: Royalties & Sales**

**Innovation & Research**
- New product development
- Patent applications
- Clinical trials

**Out-license to third-party partners**
- High margin royalty model
- Sample licensees:
  - www.1906newhighs.com
  - www.hillstreetbeverages.com

**Demonstration products**
- TurboCBD™ capsules
- ViPova™ teas

**Distribution partnerships**
Nicotine: a smoke-free future?

1.1 billion smokers globally
7 million deaths/year globally
1 billion deaths expected this century

FDA
Comprehensive regulatory plan to shift trajectory of tobacco-related disease, death

Phillip Morris
pledges $1B to anti-smoking

British American Tobacco
to rapidly expand “next-gen products”

No Nicotine edibles
due to nicotine’s inability to securely pass through the GI tract without irritation.

lowering nicotine in cigarettes to non-addictive levels

Smoking is the world’s leading cause of preventable death

“Ultimately, we want to be in a position to stop selling cigarettes entirely.”

World Health Organization (www.who.int)
Foundation for a Smoke-Free World, Inc. (www.smokefreeworld.org)
**Nicotine: In vivo research**

**Speed of onset** is of particular importance when considering non-inhalation nicotine delivery formats

DehydraTECH™ delivered:

- **90% more nicotine** delivered at 10 minute mark
  - (p=0.044)

- **70% more nicotine** delivered overall within first 15 min of study
  - (p=0.0004)

- **94% more nicotine** delivered over the 60 min study period
  - (p=0.0086)

Study of 40 lab rats, with focus on initial 15 minute period after dosing.
  - August 7, 2018

Study of 12 lab rats over 6 hour period showed 560% more nicotine delivered into brain tissue
  - April 17, 2018

179% gain in the quantity of peak nicotine delivery to the bloodstream relative to controls
## Nicotine: Blood-Brain-Barrier Results

Significant nicotine absorption increase across the Blood-Brain Barrier into brain tissue:

<table>
<thead>
<tr>
<th>Test</th>
<th>Control (10 mg/Kg)</th>
<th>DehydraTECH™ (10 mg/Kg)</th>
<th>% Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum Brain Concentration (Cmax; ng/g)</td>
<td>51.8 ± 30.4</td>
<td>290 ± 197</td>
<td>560%</td>
</tr>
<tr>
<td>Maximum Brain Concentration (Cmax; ng/g)</td>
<td>427 ± 66.5</td>
<td>1,260 ± 200</td>
<td>295%</td>
</tr>
<tr>
<td>Time to Cmax</td>
<td>4 hours</td>
<td>1 hour</td>
<td>400%</td>
</tr>
<tr>
<td>Total Quantity in Brain Tissue (AUC; hr-ng/g)</td>
<td>5,881 ± 538</td>
<td>12,999 ± 1252</td>
<td>221%</td>
</tr>
</tbody>
</table>
Serial entrepreneur involved in several private and public companies since the late 1980’s, Extensive experience in the capital markets, corporate governance, M&A and finance.

Experienced executive in the pharmaceutical and bioscience sectors, Specialist in development of drug delivery technologies, Former President and COO of Helix BioPharma Corp. (TSX: HBP), Named inventor on multiple issued and pending patents. M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto.

U.S. licensed patent attorney, Doctorate in Neuroscience (with concentrations in Pharmacology and Physiology), Over 15 years of experience providing patent services to clients that have ranged from small start-ups to some of the world’s largest pharmaceutical and biotechnology companies.

Co-Director for the Centre for Heart, Lung and Vascular Health, Canada, Research Chair in Cerebrovascular Physiology and Professor, School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.
Corporate Information

Trading symbol: LXX:CSE, LXRP:OTCQX

<table>
<thead>
<tr>
<th>Shares o/s:</th>
<th>77 m</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fully diluted:</td>
<td>85 m</td>
</tr>
<tr>
<td>Recent price:</td>
<td>C$1.70 / US$1.30</td>
</tr>
<tr>
<td>Insider ownership:</td>
<td>15m (20%)</td>
</tr>
<tr>
<td>Fiscal year-end:</td>
<td>August 31</td>
</tr>
<tr>
<td>Cash on hand (May ‘18)</td>
<td>US$ 2M</td>
</tr>
<tr>
<td>Recent financing (Oct ‘18)</td>
<td>US$1.5M (US$1.60/unit)</td>
</tr>
</tbody>
</table>

One year stock chart – OTCQX:LXRP

Chris Bunka
CEO
250 765 6424
Cbunka@lexariabioscience.com

John Docherty
President
905 439 5423
Jdocherty@lexariabioscience.com

Alex Blanchard
Manager Corp. Comm & IR
778 796-1897
Ablanchard@lexariabioscience.com